Song et al. demonstrated that FRα-specific CAR-T cells have the capacity to inhibit human TNBC growth in vivo: infused FRα-specific CAR-T cells mediated significant, albeit modest, reduction in tumor progression compared to the control mice treated with untransduced T cells (p = 0.01) or with anti-CD19 CAR-T cells (p = 0.035), as measured by caliper-based tumor size. Here, FOLR1 is linked to neoplasm.